Key facts
- This page summarizes Biohaven Pharmaceutical Holding Co Ltd.'s Form 4 filing for Biohaven Ltd. (BHVN).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 05 Oct 2022, 17:40.
Biohaven Pharmaceutical Holding Co Ltd. - 03 Oct 2022 Form 4 Insider Report for Biohaven Ltd. (BHVN)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- BHVN
- Reported as of
- 03 Oct 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Oct 2022, 17:40:23 UTC
- Prior SEC filing
- 28 Sep 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ George Clark, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Biohaven Pharmaceutical Holding Co Ltd. filed Form 4 for Biohaven Ltd. (BHVN) on 05 Oct 2022.
Change
- Previous filing in this sequence was filed on 28 Sep 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BHVN
transaction
Common Shares
Other
- Transaction value
- $0
- Shares
- +35,839,857
- Change %
- Price
- $0.000000
- Shares after
- 35,839,857
- Date
- 03 Oct 2022
- Ownership
- Direct
- Footnotes
- F1
BHVN
transaction
Common Shares
Other
- Transaction value
- $0
- Shares
- -35,839,857
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 03 Oct 2022
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On October 3, 2022, in connection with the distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") of the outstanding common shares of the Issuer ("Common Shares") pursuant to the Separation and Distribution Agreement, dated May 9, 2022, between RemainCo and the Issuer, the Issuer issued to RemainCo 35,839,857 Common Shares (the "Issuance").
Footnote F2
On October 3, 2022, immediately following the Issuance, all of the outstanding common shares of the Issuer held by RemainCo were distributed by way of a pro rata distribution to RemainCo's shareholders (the "Distribution"). As a result of the Distribution, RemainCo no longer beneficially owns any common shares of the Issuer and consequently is no longer subject to the requirements of Section 16 of the Exchange Act with respect to the Issuer.